The use of psychotropic drugs in irritable bowel syndrome

Bibliography

• Drossman DA. The functional gastrointestinal disorders and the Rome iii process. In: Drossman DA, Corazziari E, Delvaux M, Spiller RC, Talley NJ, Thompson WG, Whitehead WE, editors. Rome iii The functional gastrointestinal disorders. Degnon Associates, Inc; McLean, VA; 2006. p. 1-29
   Google Scholar
• Drossman DA, Camilleri M, Mayer EA, Whitehead WE. Aga technical review on irritable bowel syndrome. Gastroenterology 2002;123:2108-31
   PubMed Web of Science ®Google Scholar
• Gralnek I, Hays RD, Kilbourne A, The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000;119:654-60
   PubMed Web of Science ®Google Scholar
• Whitehead WE, Levy RL, Von Korff M, The usual medical care for irritable bowel syndrome. Aliment Pharmacol Ther 2004;20:1305-15
   PubMed Web of Science ®Google Scholar
• Ladabaum U, Boyd E, Zhao WK, Diagnosis, comorbidities, and management of irritable bowel syndrome in patients in a large health maintenance organization. Clin Gastroenterol Hepatol 2012;10:37-45
   PubMed Web of Science ®Google Scholar
• Dixon-Woods M, Critchley S. Medical and lay views of irritable bowel syndrome. Fam Pract 2000;17:108-13
   PubMed Web of Science ®Google Scholar
• Keszthelyi D, Troost FJ, Simren M, Revisiting concepts of visceral nociception in irritable bowel syndrome. Eur J Pain 2012;16:1444-54
   PubMed Web of Science ®Google Scholar
• Elsenbruch S. Abdominal pain in irritable bowel syndrome: a review of putative psychological, neural and neuro-immune mechanisms. Brain Behav Immun 2011;25:386-94
   PubMed Web of Science ®Google Scholar
• Drossman DA. Biopsychosocial issues in gastroenterology. In: Sleisenger MH, Fordtran JS, editors. Gastrointestinal and liver disease. W.B. Saunders Co, Philadelphia; 2010
   Google Scholar
• Posserud I, Syrous A, Lindstrom L, Altered rectal perception in irritable bowel syndrome is associated with symptom severity. Gastroenterology 2007;133:1113-23
   PubMed Web of Science ®Google Scholar
• Ludidi S, Conchillo JM, Keszthelyi D, Rectal hypersensitivity as hallmark for irritable bowel syndrome: defining the optimal cutoff. Neurogastroenterol Motil 2012;24:729-33; e345-346
   PubMed Web of Science ®Google Scholar
• Dorn SD, Palsson OS, Thiwan SI, Increased colonic pain sensitivity in irritable bowel syndrome is the result of an increased tendency to report pain rather than increased neurosensory sensitivity. Gut 2007;56:1202-9
   PubMed Web of Science ®Google Scholar
• Mayer EA. Gut feelings: the emerging biology of gut-brain communication. Nat Rev Neurosci 2011;12:453-66
   PubMed Web of Science ®Google Scholar
• Mertz H, Morgan V, Tanner G, Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention. Gastroenterology 2000;118:842-8
   PubMed Web of Science ®Google Scholar
• Naliboff BD, Derbyshire SW, Munakata J, Cerebral activation in patients with irritable bowel syndrome and control subjects during rectosigmoid stimulation. Psychosom Med 2001;63:365-75
   PubMed Web of Science ®Google Scholar
• Chang L, Berman S, Mayer EA, Brain responses to visceral and somatic stimuli in patients with irritable bowel syndrome with and without fibromyalgia. Am J Gastroenterol 2003;98:1354-61
   PubMed Web of Science ®Google Scholar
• Ringel Y, Drossman DA, Turkington TG, Regional brain activation in response to rectal distension in patients with irritable bowel syndrome and the effect of a history of abuse. Dig Dis Sci 2003;48:1774-81
   PubMed Web of Science ®Google Scholar
• Sperber AD, Drossman DA. Review article: the functional abdominal pain syndrome. Aliment Pharmacol Ther 2011;33:514-24
   PubMed Web of Science ®Google Scholar
• Seminowicz DA, Labus JS, Bueller JA, Regional gray matter density changes in brains of patients with irritable bowel syndrome. Gastroenterology 2010;139:48-57; e42
   PubMed Web of Science ®Google Scholar
• Blankstein U, Chen J, Diamant NE, Davis KD. Altered brain structure in irritable bowel syndrome. Potential contributions of pre-existing and disease-driven factors. Gastroenterology 2010;138:1783-9
   PubMed Web of Science ®Google Scholar
• Robinson ME, Craggs JG, Price DD, Gray matter volumes of pain-related brain areas are decreased in fibromyalgia syndrome. J Pain 2011;12:436-43
   PubMed Web of Science ®Google Scholar
• Phillips K, Clauw DJ. Central pain mechanisms in chronic pain states--maybe it is all in their head. Best Pract Res Clin Rheumatol 2011;25:141-54
   PubMed Web of Science ®Google Scholar
• Yang PC, Jury J, Soderholm JD, Chronic psychological stress in rats induces intestinal sensitization to luminal antigens. Am J Pathol 2006;168:104-14; quiz 363
   PubMed Web of Science ®Google Scholar
• Barbara G, Cremon C, Carini G, The immune system in irritable bowel syndrome. J Neurogastroenterol Motil 2011;17:349-59
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Kanazawa M, Fukudo S, Drossman DA. Biopsychosocial model of irritable bowel syndrome. J Neurogastroenterol Motil 2011;17:131-9
   PubMed Web of Science ®Google Scholar
• Drossman DA. Abuse, trauma, and gi illness: is there a link? Am J Gastroenterol 2011;106:14-25
   PubMed Web of Science ®Google Scholar
• Bradford K, Shih W, Videlock EJ, Association between early adverse life events and irritable bowel syndrome. Clin Gastroenterol Hepatol 2012;10:385-90; e381-383
   PubMed Web of Science ®Google Scholar
• Lackner JM, Jaccard J, Krasner SS, Self-administered cognitive behavior therapy for moderate to severe irritable bowel syndrome: clinical efficacy, tolerability, feasibility. Clin Gastroenterol Hepatol 2008;6:899-906
   PubMed Web of Science ®Google Scholar
• Kennedy TM, Chalder T, McCrone P, Cognitive behavioural therapy in addition to antispasmodic therapy for irritable bowel syndrome in primary care: randomised controlled trial. Health Technol Assess 2006;10:iii-v; ix-x, 1-67
   PubMedGoogle Scholar
• Blanchard EB, Lackner JM, Sanders K, A controlled evaluation of group cognitive therapy in the treatment of irritable bowel syndrome. Behav Res Ther 2007;45:633-48
   PubMed Web of Science ®Google Scholar
• Blanchard EB, Schwarz SP, Suls JM, Two controlled evaluations of multicomponent psychological treatment of irritable bowel syndrome. Behav Res Ther 1992;30:175-89
   PubMed Web of Science ®Google Scholar
• Lindfors P, Unge P, Arvidsson P, Effects of gut-directed hypnotherapy on ibs in different clinical settings-results from two randomized, controlled trials. Am J Gastroenterol 2012;107:276-85
   PubMed Web of Science ®Google Scholar
• Gaylord SA, Palsson OS, Garland EL, Mindfulness training reduces the severity of irritable bowel syndrome in women: results of a randomized controlled trial. Am J Gastroenterol 2011;106:1678-88
   PubMed Web of Science ®Google Scholar
• Bryson HM, Wilde MI. Amitriptyline. A review of its pharmacological properties and therapeutic use in chronic pain states. Drugs Aging 1996;8:459-76
   PubMed Web of Science ®Google Scholar
• Arnold LM, Keck PE Jr, Welge JA. Antidepressant treatment of fibromyalgia. A meta-analysis and review. Psychosomatics 2000;41:104-13
   PubMed Web of Science ®Google Scholar
• Dharmshaktu P, Tayal V, Kalra BS. Efficacy of antidepressants as analgesics: a review. J Clin Pharmacol 2012;52:6-17
   PubMed Web of Science ®Google Scholar
• Halpert A, Dalton CB, Diamant NE, Clinical response to tricyclic antidepressants in functional bowel disorders is not related to dosage. Am J Gastroenterol 2005;100:664-71
   PubMed Web of Science ®Google Scholar
• Creed F, Guthrie E, Ratcliffe J, North of England IBSRG: Does psychological treatment help only those patients with severe irritable bowel syndrome who also have a concurrent psychiatric disorder? Aust N Z J Psychiatry 2005;39:807-15
   PubMed Web of Science ®Google Scholar
• Max MB, Culnane M, Schafer SC, Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology 1987;37:589-96
   PubMed Web of Science ®Google Scholar
• Ruepert L, Quartero AO, de Wit NJ, Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2011;8:CD003460
   PubMed Web of Science ®Google Scholar
• Ford AC, Talley NJ, Schoenfeld PS, Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009;58:367-78
   PubMed Web of Science ®Google Scholar
• Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis. World J Gastroenterol 2009;15:1548-53
   PubMed Web of Science ®Google Scholar
• Drossman DA, Toner BB, Whitehead WE, Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 2003;125:19-31
   PubMed Web of Science ®Google Scholar
• Max MB, Lynch SA, Muir J, Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992;326:1250-6
   PubMed Web of Science ®Google Scholar
• Sindrup SH, Gram LF, Brosen K, The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 1990;42:135-44
   PubMed Web of Science ®Google Scholar
• Sindrup SH, Bjerre U, Dejgaard A, The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther 1992;52:547-52
   PubMed Web of Science ®Google Scholar
• Perrot S, Javier RM, Marty M, Cedr FRSPSS. Is there any evidence to support the use of anti-depressants in painful rheumatological conditions? Systematic review of pharmacological and clinical studies. Rheumatology (Oxford) 2008;47:1117-23
   PubMed Web of Science ®Google Scholar
• Wernicke JF, Pritchett YL, D'Souza DN, A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006;67:1411-20
   PubMed Web of Science ®Google Scholar
• Moja PL, Cusi C, Sterzi RR, Canepari C. Selective serotonin re-uptake inhibitors (ssris) for preventing migraine and tension-type headaches. Cochrane Database Syst Rev 2005;3:CD002919
   PubMedGoogle Scholar
• Smith B, Peterson K, Fu R, Drug class review: Drugs for fibromyalgia: Final original report. Portland 2011
   Google Scholar
• Creed F, Fernandes L, Guthrie E, The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 2003;124:303-17
   PubMed Web of Science ®Google Scholar
• Tabas G, Beaves M, Wang J, Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial. Am J Gastroenterol 2004;99:914-20
   PubMed Web of Science ®Google Scholar
• Masand PS, Pae CU, Krulewicz S, A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome. Psychosomatics 2009;50:78-86
   PubMed Web of Science ®Google Scholar
• Kuiken SD, Tytgat GN, Boeckxstaens GE. The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. Clin Gastroenterol Hepatol 2003;1:219-28
   PubMed Web of Science ®Google Scholar
• Vahedi H, Merat S, Rashidioon A, The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study. Aliment Pharmacol Ther 2005;22:381-5
   PubMed Web of Science ®Google Scholar
• Tack J, Broekaert D, Fischler B, A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut 2006;55:1095-103
   PubMed Web of Science ®Google Scholar
• Talley NJ, Kellow JE, Boyce P, Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial. Dig Dis Sci 2008;53:108-15
   PubMed Web of Science ®Google Scholar
• Brecht S, Courtecuisse C, Debieuvre C, Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial. J Clin Psychiatr 2007;68:1707-16
   PubMed Web of Science ®Google Scholar
• Gaynor PJ, Gopal M, Zheng W, Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study. Curr Med Res Opin 2011;27:1859-67
   PubMed Web of Science ®Google Scholar
• Brennan BP, Fogarty KV, Roberts JL, Jr, Hudson JI. Duloxetine in the treatment of irritable bowel syndrome: an open-label pilot study. Hum Psychopharmacol 2009;24:423-8
   PubMed Web of Science ®Google Scholar
• Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev 2007;4:CD005454
   PubMedGoogle Scholar
• Chial HJ, Camilleri M, Ferber I, Effects of venlafaxine, buspirone, and placebo on colonic sensorimotor functions in healthy humans. Clin Gastroenterol Hepatol 2003;1:211-18
   PubMed Web of Science ®Google Scholar
• van Kerkhoven LA, Laheij RJ, Aparicio N, Effect of the antidepressant venlafaxine in functional dyspepsia: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2008;6:746-52; quiz 718
   PubMed Web of Science ®Google Scholar
• Calandre EP, Rico-Villademoros F. The role of antipsychotics in the management of fibromyalgia. CNS Drugs 2012;26:135-53
   PubMed Web of Science ®Google Scholar
• Potvin S, Morin M, Cloutier C, Add-on treatment of quetiapine for fibromyalgia: a pilot, randomized, double-blind, placebo-controlled 12-week trial. J Clin Psychopharmacol 2012;32:684-7
   PubMed Web of Science ®Google Scholar
• Grover M, Dorn SD, Weinland SR, Atypical antipsychotic quetiapine in the management of severe refractory functional gastrointestinal disorders. Dig Dis Sci 2009;54:1284-91
   PubMed Web of Science ®Google Scholar
• Freedenfeld RN, Murray M, Fuchs PN, Kiser RS. Decreased pain and improved quality of life in fibromyalgia patients treated with olanzapine, an atypical neuroleptic. Pain Pract 2006;6:112-18
   PubMedGoogle Scholar
• Stimmel GL, Dopheide JA, Stahl SM. Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects. Pharmacotherapy 1997;17:10-21
   PubMed Web of Science ®Google Scholar
• Yin J, Wang W, Winston JH, Ameliorating effects of mirtazapine on visceral hypersensitivity in rats with neonatal colon sensitivity. Neurogastroenterol Motil 2010;22:1022-8; e1267
   PubMed Web of Science ®Google Scholar
• Choung RS, Cremonini F, Thapa P, The effect of short-term, low-dose tricyclic and tetracyclic antidepressant treatment on satiation, postnutrient load gastrointestinal symptoms and gastric emptying: a double-blind, randomized, placebo-controlled trial. Neurogastroenterol Motil 2008;20:220-7
   PubMed Web of Science ®Google Scholar
• Thomas SG. Irritable bowel syndrome and mirtazapine. Am J Psychiatry 2000;157:1341-2
   PubMed Web of Science ®Google Scholar
• Spiegel DR, Kolb R. Treatment of irritable bowel syndrome with comorbid anxiety symptoms with mirtazapine. Clin Neuropharmacol 2011;34:36-8
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Fava M, Wisniewski SR, Medication augmentation after the failure of ssris for depression. N Engl J Med 2006;354(12):1243-52
   PubMed Web of Science ®Google Scholar
• Bradley RH, Barkin RL, Jerome J, Efficacy of venlafaxine for the long term treatment of chronic pain with associated major depressive disorder. Am J Ther 2003;10:318-23
   PubMedGoogle Scholar
• Tack J, Janssen P, Masaoka T, Efficacy of buspirone, a fundus-relaxing drug, in patients with functional dyspepsia. Clin Gastroenterol Hepatol 2012;10:1239-45
   PubMed Web of Science ®Google Scholar
• Drossman DA. Psychosocial sound bites: exercises in the patient-doctor relationship. Am J Gastroenterol 1997;92:1418-23
   PubMed Web of Science ®Google Scholar
• Thiwan S, Drossman DA, Morris CB, Not all side effects associated with tricyclic antidepressant therapy are true side effects. Clin Gastroenterol Hepatol 2009;7:446-51
   PubMed Web of Science ®Google Scholar
• Grover M, Drossman DA. Psychopharmacologic and behavioral treatments for functional gastrointestinal disorders. Gastrointest Endosc Clin N Am 2009;19:151-70
   PubMedGoogle Scholar
• Grover M, Drossman DA. Centrally acting therapies for irritable bowel syndrome. Gastroenterol Clin N Am 2011;40:183-206
   PubMed Web of Science ®Google Scholar
• Drossman DA. Beyond tricyclics: new ideas for treating patients with painful and refractory functional gastrointestinal symptoms. Am J Gastroenterol 2009;104:2897-902
   PubMed Web of Science ®Google Scholar
• Shah E, Kim S, Chong K, Evaluation of harm in the pharmacotherapy of irritable bowel syndrome. Am J Med 2012;125:381-93
   PubMed Web of Science ®Google Scholar
• Gralnek IM, Hays RD, Kilbourne A, The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000;119:654-60
   PubMed Web of Science ®Google Scholar
• Frank L, Kleinman L, Rentz A, Health-related quality of life associated with irritable bowel syndrome: comparison with other chronic diseases. Clin Ther 2002;24:675-89
   PubMed Web of Science ®Google Scholar